Becton, Dickinson and Company Launches Syringe Which Addresses Environmental Impact Whilst Meeting a Number of Clinical Needs

Oxford, UK (3rd January 2013) - BD (Becton, Dickinson and Company) recently announced the launch of the BD EmeraldTM, a syringe for general medication preparation and delivery, which also enjoys the advantage of being designed to contribute to a reduction in medical waste in all communities (http://www.bd.com/emerald/en/).

“BD recognises that human health and a healthy environment are inseparable,” said Roland Goette, VP / GM Western Europe, BD Medical – Medical Surgical Systems, “and we are committed to responsible environmental stewardship in our business conduct. The BD Emerald™ Syringe meets our highest standards for product quality while also reducing environmental impact by using less material and sustainable operations practices.”

The BD EmeraldTM Conventional Syringe for general medication preparation and delivery is part of the BD EmeraldTM Syringe portfolio which helps to prevent the spread of infection by addressing clinical needs and meeting exacting quality standards around the world.

The BD Emerald™ Syringe is manufactured using sustainable manufacturing practices, including the use of renewable electricity, at a BD facility in Spain, and uses less material in the manufacturing process. This will, in turn, help hospitals to reduce their medical waste in line with NHS carbon footprint targets.

The BD EmeraldTM Syringe product line builds upon BD's sustainability commitment, which has been recognised for achievements in environmental stewardship. To learn more about environmental stewardship at BD, visit www.bd.com/sustainability.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com